Citadel Advisors’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-42,777
| Closed | -$22.6K | – | 15802 |
|
|
2025
Q1 | $22.6K | Buy |
+42,777
| New | +$70.5K | ﹤0.01% | 13053 |
|
|
2024
Q3 | – | Sell |
-8,912
| Closed | -$144K | – | 15515 |
|
|
2024
Q2 | $144K | Hold |
8,912
| – | – | ﹤0.01% | 10399 |
|
|
2024
Q1 | $902K | Sell |
8,912
-956
| -10% | -$60.4K | ﹤0.01% | 7134 |
|
|
2023
Q4 | $233K | Buy |
9,868
+1,427
| +17% | +$24K | ﹤0.01% | 9647 |
|
|
2023
Q3 | $174K | Sell |
8,441
-24,585
| -74% | -$477K | ﹤0.01% | 10136 |
|
|
2023
Q2 | $859K | Buy |
33,026
+1,830
| +6% | +$52.4K | ﹤0.01% | 6775 |
|
|
2023
Q1 | $649K | Hold |
31,196
| – | – | ﹤0.01% | 7752 |
|
|
2022
Q4 | $636K | Sell |
31,196
-82
| -0.3% | -$1.54K | ﹤0.01% | 7747 |
|
|
2022
Q3 | $863K | Buy |
31,278
+82
| +0.3% | +$2.36K | ﹤0.01% | 7314 |
|
|
2022
Q2 | $824K | Sell |
31,196
-23
| -0.1% | -$1.02K | ﹤0.01% | 7475 |
|
|
2022
Q1 | $2.5M | Sell |
31,219
-18
| -0.1% | -$2.22K | ﹤0.01% | 5601 |
|
|
2021
Q4 | $6.37M | Sell |
31,237
-72
| -0.2% | -$18K | ﹤0.01% | 3871 |
|
|
2021
Q3 | $10.1M | Sell |
31,309
-498
| -2% | -$145K | ﹤0.01% | 3055 |
|
|
2021
Q2 | $8.26M | Buy |
31,807
+10,296
| +48% | +$3.14M | ﹤0.01% | 3419 |
|
|
2021
Q1 | $8.3M | Buy |
+21,511
| New | +$8.68M | ﹤0.01% | 3266 |
|
Other funds holding VINC
Citadel Advisors's VINC Position: Q2 2025 in Review
Citadel Advisors sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2025, closing a stake of 42,777 shares — an estimated $22.6K sold.
Citadel Advisors first reported a position in VINC in Q1 2021 and held it in 15 quarters. The position peaked at $10.1M in Q3 2021. 1 fund tracked by Wall St. Rank holds VINC as of Q2 2025.
- Citadel Advisors reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 42,777 Vincerx Pharma, Inc. Common Stock shares in Q2 2025, an estimated $22.6K.
- Citadel Advisors first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 15 quarters.
- Citadel Advisors's Vincerx Pharma, Inc. Common Stock position peaked at $10.1M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.